Genome Identification Diagnostics GmbH

Their core work

Genome Identification Diagnostics GmbH (GID) is a German diagnostics SME focused on molecular and DNA-based identification methods for infectious diseases. Their demonstrated expertise lies in tuberculosis diagnostics — including detection of latent TB infection and genotypic profiling of drug susceptibility, which is critical for managing multi-drug-resistant TB cases. They contribute specialist diagnostic technology and methodology to clinical and translational research consortia, rather than conducting broad-spectrum research themselves. Their participation in both a large clinical cell therapy trial (PACE) and a TB innovation program (INNOVA4TB) suggests they provide diagnostic services and tools that support a range of biomedical research designs.

What they specialise in

How they've shifted over time

GID's first recorded H2020 project (PACE, 2017) was a clinical cell therapy trial with no disease-specific diagnostic keywords attached to their participation, suggesting a general diagnostic services role at that stage. By 2019, their engagement in INNOVA4TB showed a clear and specific focus on tuberculosis — latent TB detection and genotypic drug susceptibility profiling — indicating a deliberate narrowing toward infectious disease molecular diagnostics. The trajectory points to deliberate specialization in TB diagnostics rather than broad-base growth.

GID is moving toward deeper specialization in genotype-based TB diagnostics, a field with growing demand as drug-resistant TB strains require faster and more precise identification tools globally.

How they like to work

GID has participated exclusively as a consortium partner, never as project coordinator, which positions them as a specialist contributor rather than a project driver. Their two projects collectively involved 26 unique partners across 12 countries, indicating comfort operating within large, internationally distributed consortia. Partners should expect GID to deliver focused diagnostic expertise within a defined work package rather than broad cross-cutting contributions.

GID has built a surprisingly wide network for a two-project SME — 26 unique partners across 12 countries, pointing to participation in large multinational consortia. No geographic concentration is evident from available data.

What sets them apart

GID occupies a narrow but high-value niche: genotypic drug susceptibility testing for tuberculosis is technically demanding, commercially relevant, and underserved by large diagnostics firms. As a small German SME with validated EU project experience in both clinical trials and TB innovation programs, they bring private-sector agility alongside demonstrated capacity to operate in regulated, multi-center research environments. For consortium builders targeting infectious disease diagnostics — particularly TB — GID offers specialist credentials that few SMEs of their size can match.

Highlights from their portfolio

• PACE
  GID's largest funded project (EUR 161,000), a phase IIb multicenter clinical trial on placenta-derived cell therapy — their participation here demonstrates diagnostic support capacity well beyond their TB-specific niche.
• INNOVA4TB
  Most directly aligned with GID's core expertise, this TB innovation project is the clearest evidence of their specialist positioning in latent TB detection and genotypic drug susceptibility profiling.